Tinzaparin: Considerations for Use in Clinical Practice
Authors:
- 1 December 2003
- journal article
- research article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 37 (12) , 1831-1840
Abstract
OBJECTIVE: To evaluate the safety and effectiveness of tinzaparin for the prevention and treatment of venous thromboembolism (VTE). DATA SOURCES: A MEDLINE and PubMed database search (1980–December 2002) was conducted. Only articles written in English were reviewed. STUDY SELECTION AND DATA EXTRACTION: Articles reporting the safety, efficacy, and cost-effectiveness of tinzaparin in humans were evaluated. Emphasis was placed on randomized, controlled trials. DATA SYNTHESIS: Tinzaparin sodium is a low-molecular-weight heparin (LMWH) that exerts its anticoagulant effect through inhibition of factors Xa and IIa and release of tissue factor pathway inhibitor from the vascular epithelium. Tinzaparin is indicated for treatment of acute symptomatic deep-vein thrombosis (DVT), with or without pulmonary embolism. Clinical studies suggest that tinzaparin is also effective for VTE prophylaxis, as well as other indications. Once-daily subcutaneous tinzaparin is equally or more effective than intravenous unfractionated heparin (UFH) for prevention and treatment of VTE, at least as safe as UFH for bleeding complications, and requires little or no monitoring. No dose “cap” is required for obese patients, and no initial dosing adjustments are necessary in elderly and/or renally impaired patients, although some monitoring is recommended. The few comparative data available suggest that tinzaparin efficacy may be comparable to that of other LMWHs; more comparative studies are needed. Pharmacoeconomic studies indicate a favorable cost—benefit ratio. CONCLUSIONS: Tinzaparin is safe and effective for prevention and treatment of DVT. Consistent once-daily dosing may facilitate self-administration of tinzaparin in the outpatient setting.Keywords
This publication has 38 references indexed in Scilit:
- Incidence and prevention of deep venous thrombosis occurring late after general surgery: randomised controlled study of prolonged thromboprophylaxisBritish Journal of Surgery, 2003
- Mutations associated with hemophilia A in the 558-565 loop of the factor VIIIa A2 subunit alter the catalytic activity of the factor Xase complexBlood, 2002
- Safety Profile of Tinzaparin Administered Once Daily at a Standard Curative Dose in Two Hundred Very Elderly PatientsDrug Safety, 2002
- Myocardial ischemia and infarctionJACC, 2001
- An Equivalence Study of Two Low-Molecular-Weight Heparins in the Prevention and Treatment of Deep-Vein Thrombosis after Total Hip ReplacementSeminars in Thrombosis and Hemostasis, 2000
- Dose Titration Study of Tinzaparin, a Low Molecular Weight Heparin, in Patients on Chronic HemodialysisArtificial Organs, 1998
- Economic evaluation of the use of Innohep® in the treatment of acute pulmonary embolismJournal of Medical Economics, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Acute Pulmonary EmbolismNew England Journal of Medicine, 1997
- Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin™). An experimental investigation in healthy volunteersBlood Coagulation & Fibrinolysis, 1994